REVENUE RECOGNITION - Narrative (Details) $ in Millions |
6 Months Ended | |
|---|---|---|
|
Jun. 30, 2025
USD ($)
pharmacy
|
Jun. 30, 2024
USD ($)
|
|
| Disaggregation of Revenue [Line Items] | ||
| Number of direct-to-patient pharmacies sold to | pharmacy | 2 | |
| Revenue, performance obligation, description of timing | For FILSPARI, sales are recognized upon delivery of the product to the specialty pharmacies. The Company receives payments from its FILSPARI sales based on terms that are generally 30 days from shipment of the product to the specialty pharmacy. For the Company's tiopronin products, product sales are recognized upon delivery to the patient. The Company receives payments from sales of its tiopronin products, primarily through third party payers, based on terms that generally are within 30 days of delivery of product to the patient. | |
| Revenue increase (decrease) in performance obligations satisfied in previous period | $ | $ (1.3) | $ 0.2 |
| Geographic Concentration Risk | Revenue Benchmark | United States | ||
| Disaggregation of Revenue [Line Items] | ||
| Concentration risk, percentage | 98.00% | |